Table 2.
Univariate Analysis for Cycle 1 Severe or Febrile Neutropenia
| Variables | No. | Percentage (%)Cycle 1 SN or FN | P | |
|---|---|---|---|---|
| Derivation N=2425 | Validation N=1213 | |||
| All patients | 3638 | 19.5 | 21.2 | .221 |
| Age, y | ||||
| ≥65 | 1384 | 17.7 | 17.9 | .916 |
| <65 | 2254 | 20.5 | 23.2 | |
| P | .091 | .030 | ||
| Prior chemotherapy | ||||
| Yes | 847 | 15.1 | 14.0 | .662 |
| No | 2787 | 20.8 | 23.2 | |
| P | .002 | .001 | ||
| Baseline Labs | ||||
| AST>35 U/L | ||||
| Yes | 458 | 22.5 | 23.8 | .757 |
| No | 3068 | 18.7 | 21.2 | |
| P | .122 | .454 | ||
| AP>120 U/L | ||||
| Yes | 688 | 19.1 | 20.7 | .615 |
| No | 2853 | 19.3 | 21.7 | |
| P | .947 | .790 | ||
| Bilirubin>1 mg/dL | ||||
| Yes | 147 | 27.7 | 32.1 | .572 |
| No | 3388 | 19.0 | 21.0 | |
| P | .045 | .061 | ||
| GFR<60 mL/min | ||||
| Yes | 703 | 21.9 | 18.8 | .334 |
| No | 2935 | 18.9 | 21.7 | |
| P | .137 | .369 | ||
| WBC<5000/mm3 | ||||
| Yes | 485 | 23.3 | 25.0 | .673 |
| No | 3153 | 18.9 | 20.5 | |
| P | .077 | .195 | ||
| Cancer type | ||||
| Colorectum | 495 | 4.5 | 5.6 | .609 |
| Small cell lung | 198 | 27.7 | 31.1 | .625 |
| Nonsmall cell lung | 665 | 9.3 | 11.1 | .178 |
| Ovary | 303 | 10.8 | 11.1 | .932 |
| Breast | 1443 | 29.0 | 32.0 | .237 |
| Lymphoma | 534 | 23.0 | 25.3 | .555 |
| P | <.001 | <.001 | ||
| Medications | ||||
| Immunosuppressives | ||||
| Yes | 516 | 24.9 | 21.0 | .321 |
| No | 3122 | 18.5 | 21.2 | |
| P | .007 | .999 | ||
| Planned RDI | ||||
| ≥85% | 2546 | 22.3 | 24.2 | .273 |
| <85% | 849 | 12.5 | 11.7 | .737 |
| Nonstandard | 243 | 13.9 | 23.4 | .065 |
| P | <.001 | <.001 | ||
| Chemotherapy | ||||
| Anthracyclines | ||||
| Yes | 1438 | 34.5 | 37.3 | .289 |
| No | 2200 | 10.1 | 9.6 | |
| P | <.001 | <.001 | ||
| Platinums | ||||
| Yes | 1150 | 11.7 | 10.5 | .558 |
| No | 2488 | 23.1 | 25.9 | |
| P | <.001 | <.001 | ||
| Taxanes | ||||
| Yes | 1048 | 13.6 | 15.7 | .356 |
| No | 2590 | 21.9 | 23.3 | |
| P | <.001 | .004 | ||
| Alkylating agents | ||||
| Yes | 1586 | 32.0 | 33.0 | .699 |
| No | 2052 | 10.1 | 11.4 | |
| P | <.001 | <.001 | ||
| Topoisomerase II inhibitors | ||||
| Yes | 223 | 30.7 | 35.6 | .458 |
| No | 3415 | 18.7 | 20.3 | |
| P | .001 | .003 | ||
| Gemcitabine | ||||
| Yes | 241 | 13.8 | 9.9 | .390 |
| No | 3397 | 19.9 | 22.0 | |
| P | .063 | .007 | ||
| Topoisomerase I inhibitors | ||||
| Yes | 39 | 25.0 | 45.5 | .213 |
| No | 3599 | 19.4 | 21.0 | |
| P | .471 | .062 | ||
| Vinorelbine | ||||
| Yes | 111 | 15.4 | 6.1 | .176 |
| No | 3527 | 19.6 | 21.6 | |
| P | .467 | .030 | ||
| Primary CSF prophylaxis | ||||
| Yes | 772 | 6.4 | 9.8 | .081 |
| No | 2866 | 22.8 | 24.7 | |
| P | <.001 | <.001 | ||
RDI indicates relative dose intensity; GFR, glomerular filtration rate; AST, aspartate aminotransferase; SN, severe neutropenia; FN, febrile neutropenia; WBC, white blood count; AP, alkaline phosphatase; CSF, colony-stimulating factors.